A Label-Free blocking immunoassay to evaluate Anti-Adalimumab antibody activity in clinical samples
The LF-BIA may provide an efficient approach to specifically measure blocking ADAs rather than total ADAs. Alongside with previously reported applications of label-free immunoassays in clinical testing, the LF-BIA highlights a promising area in which label-free technologies such as BLI can play an important role.
Authors
- Ruben Yiqi Luo (ORCID: https://orcid.org/0000-0003-4483-8369)
- Nigel Taylor (ORCID: https://orcid.org/0009-0000-0189-055X)
- Yonghua Liu (ORCID: https://orcid.org/0000-0002-3637-7796)
- N Iwai
- Judi Abdelrazik
Institutions
- Stanford Health Care (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Mass Spectrometry and Advances in the Clinical Lab
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.jmsacl.2025.10.006
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00